A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This study is testing a new drug called TER-2013 for people with advanced solid tumors that have specific genetic changes in a pathway called AKT/PI3K/PTEN. This pathway, when altered, can drive cancer growth. The drug may be given alone or combined with another hormone-blocking drug (fulvestrant) for certain breast cancers. **You may be eligible if...** - You have advanced or metastatic solid tumor cancer that cannot be cured with current treatments - Your tumor has a confirmed AKT, PI3K, or PTEN genetic change - You are in reasonably good physical condition (able to carry out normal daily activities) - Depending on the group: you have ovarian, cervical, head and neck, lung, esophageal, or endometrial cancer (monotherapy), or hormone receptor-positive, HER2-negative breast cancer (combination group) - You have received prior standard treatments **You may NOT be eligible if...** - Your tumor has certain other driver mutations (EGFR, KRAS, BRAF, etc.) alongside the PI3K/AKT change - You have active brain metastases - You have uncontrolled blood sugar problems - You have had an AKT or PI3K inhibitor before (for expansion cohorts) - You have severe gut problems that would prevent absorbing the drug Talk to your doctor to see if this trial is right for you.